(GLY14)-HUMANIN (HUMAN) manufacturers
|
| | (GLY14)-HUMANIN (HUMAN) Basic information |
| | (GLY14)-HUMANIN (HUMAN) Chemical Properties |
| storage temp. | −70°C | | form | solid | | color | White to off-white | | biological source | human | | Water Solubility | water: 1.00-1.04mg/mL, clear, colorless | | InChIKey | WUYRHUFIUFJVQU-LIRFXKSTNA-N |
| | (GLY14)-HUMANIN (HUMAN) Usage And Synthesis |
| Uses | [Gly14]-Humanin G human has been used:- along with bortezomib in pharmacological inhibition studies to tre at mice to limit the toxic effects of bortezomib
- to study its effect on high glucose (HG)-induced apoptosis of endothelial cells (ECs)
- to study its neuroprotective effects in an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model using SH-SY5Y neuroblastoma cells
', '[Gly1]-Humanin G human has been used to limit the toxicity during the bortezomib treatment in neonatal brachial plexus injury (NBPI) mice model. It has also been used in the cell culture of the human-derived neuroblastoma cell line. | | Biological Activity | Endogenous rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimerμs disease genes and Aβ', '[Gly14]-humanin (HNG) stimulates cell growth, proliferation, and cell cycle progression. It enhances proteins such as kinases, transporters, transmembrane receptors, and transcription and translational regulators. HNG exhibits intense in vitro neuroprotective effects compared to natural HN. Studies show th at it is an effective cytoprotectant both in vitro and in vivo. HNG is found to prevent high glucose (HG)-induced apoptosis of endothelial cells (ECs). It is proven to inhibit AngII-induced phenotypic switch in vascular smooth muscle cells (VSMCs). | | in vivo | (Gly14)-Humanin (human) (0.1 μg/5 μL; i.c.v.; once) decreases cells with plasmalemma permeability in the injured cortex and hippocampus, reduces brain lesion volume, improves motor performance and ameliorates performance in the Morris water maze test[2]. | Animal Model: | Adult male CD-1 mice (25-30 g; 10-12-week-old) bearing traumatic brain injury (TBI)[2] | | Dosage: | 0.1 μg/5 μL | | Administration: | Intracerebroventricularly (i.c.v.); once | | Result: | Decreased cells with plasmalemma permeability in the injured cortex and hippocampus, reduced brain lesion volume, improved motor performance. |
|
| | (GLY14)-HUMANIN (HUMAN) Preparation Products And Raw materials |
|